[ Visit Client Website ]

Before you can access ASH's online program, you must agree to the following:
  • Abstracts submitted to the ASH Annual Meeting are considered embargoed from the time of submission.
  • The media, companies and institutions issuing press releases, and others are required to abide by the embargo policies governing the Society’s annual meeting. Read ASH’s embargo policy for more information.
Last updated October 26, 2010. Please note that this site represents the latest program changes
and differs from the print version in some details.

111.P1.70 Hemoglobinopathies, Excluding Thalassemia Poster I

Oral and Poster Abstracts
Poster Session
Saturday, December 6, 2008: 5:30 PM-7:30 PM
Hall A (Moscone Center)
Urine Concentrating Ability in Infants with Sickle Cell Anemia: Baseline Data from the BABY HUG Trial

Scott T. Miller, MD1, Winfred C. Wang, MD2, Rathi V. Iyer, MD3*, Sohail R Rana, MD4*, Peter A. Lane Jr., MD5*, Russell E. Ware, MD, PhD2, Renee C Rees, PhD6* and The BABY HUG Investigators6*

1SUNY - Brooklyn, Brooklyn, NY
2St. Jude Children's Research Hospital, Memphis, TN
3Pediatrics, University of Mississippi Medical Center, Jackson, MS
4Department of Pediatric and Child Health, Howard University Hospital, Washington DC, DC
5School of Medicine, Emory University, Atlanta, GA
6Clinical Trials & Surveys, Corp., Baltimore, MD

Renal Function in Infants with Sickle Cell Anemia:  Baseline Data from the BABY HUG Trial

Russell E. Ware, MD, PhD1, Renee C. Rees, PhD2*, Sharada A. Sarnaik, MD3, Rathi V. Iyer, MD4*, Ofelia A. Alvarez, MD5, James F. Casella, MD6, Barry L. Shulkin, MD1*, Eglal Shalaby-Rana, MD7*, C. Frederic Strife, MD8*, John H. Miller, MD9*, Peter A. Lane Jr., MD10*, Winfred C. Wang1*, Scott T. Miller, MD11 and The BABY HUG Investigators2*

1St. Jude Children's Research Hospital, Memphis, TN
2Clinical Trials & Surveys, Corp., Baltimore, MD
3Children's Hosp. of Michigan, Detroit, MI
4University of Mississippi Medical Ctr, Jackson, MS
5Univ. of Miami School of Med., Miami, FL
6Pediatrics, Johns Hopkins Univ. School of Med., Baltimore, MD
7Radiology, Children's National Medical Center, Washington DC
8Cincinnati Children's Hospital Medical Center, Cincinnait, OH
9Radiology, Harbor - UCLA Medical Center, Torrance, CA
10School of Medicine, Emory University, Atlanta, GA
11SUNY - Brooklyn, Brooklyn, NY

Chloroquine Modulates Arginase Activity by Limiting the Availability of Intracellular Mobile Iron Pool in Human Erythroid Cells

Efemwonkiekie W Iyamu, PhD, MD*, Harrison A Perdew, BS* and Gerald M Woods, MD*

Pediatrics, Children's Mercy Hospital, Kansas City, MO

Spleen Function in Infants with Sickle Cell Anemia:  Baseline Data from the BABY HUG Trial

Zora R. Rogers, MD1, Renee C. Rees, PhD2*, Beatrice Files, MD2*, Rathi V. Iyer, MD3*, Barry L. Shulkin, MD4*, Eglal Shalaby-Rana, MD5*, John H. Miller, MD6*, Stephen D. Dertinger, PhD7*, Peter A. Lane, MD8*, Winfred C. Wang, MD4, Russell E. Ware, MD, PhD4 and The BABY HUG Investigators2*

1Department of Pediatrics, UT Southwestern Medical Center, Dallas, TX
2Clinical Trials & Surveys, Corp., Baltimore, MD
3University of Mississippi, Jackson, MS
4St. Jude Children's Research Hospital, Memphis, TN
5Children's National Medical Center, Washington DC
6Harbor-UCLA Medical Center, Torrance, CA
7Litron Laboratories, Rochester, NY
8Emory University School of Medicine, Atlanta, GA

A Short Course of Prednisone in the Management of Acute Chest Syndrome of Sickle Cell Disease

Riten Kumar, MD1*, Shahina Qureshi, MD2*, Prita Mohanty, MD2*, Sreedhar P Rao, MD2* and Scott T. Miller, MD2

1Pediatric Hematology Oncology, Mayo Clinic, Rochester, MN
2SUNY - Brooklyn, Brooklyn, NY

Allosteric Hemoglobin Effector Loaded Erythrocytes Improve the Efficiency of Transfusion to Prevent Sickling

Vanessa Bourgeaux1*, Olivier Hecquet2*, Dominique Rigal2*, Alain Francina3* and Yann Godfrin1*

1ERYtech Pharma, Lyon, France
2Etablissement Français du Sang - Rhône-Alpes, Lyon, France
3Unité de Pathologie Moléculaire, Hôpital Edouard Herriot, Lyon, France

Deferasirox Efficacy and Safety for the Treatment of Transfusion-Dependent Iron Overload in Patients with a Range of Rare Anemias

John B Porter1*, Kai-Hsin Lin2*, Dany Habr3*, Gabor Domokos4*, Abdel Hmissi4* and Swee Lay Thein5

1University College London, London, United Kingdom
2National Taiwan University Hospital, Taipei, Taiwan
3Novartis, East Hanover, NJ
4Novartis, Basel, Switzerland
5Department of Haematology, King's College Hospital, London, United Kingdom

Deferasirox (Exjade®), the Once-Daily Oral Iron Chelator, Demonstrates Safety and Efficacy in Patients with Sickle Cell Disease (SCD): 3.5-Year Follow-upClinically Relevant Abstract

Elliott Vichinsky1, Thomas Coates2, Alexis A Thompson3*, Françoise Bernaudin4*, Martha Rodriguez5*, Lisa Rojkjaer6* and Matthew M Heeney7*

1Children's Hospital and Research Center Oakland, Oakland, CA
2Children's Hospital Los Angeles, Los Angeles, CA
3Children's Memorial Hospital, Chicago, IL
4Centre Hospitalier Intercommunal, Créteil, France
5Novartis, East Hanover, NJ
6Novartis, Basel, Switzerland
7Children's Hospital Boston, Boston, MA

Serum Ferritin Predicts Liver but Not Cardiac Iron Burden by Noninvasive MRI in Sickle Cell Disease (SCD

Robert I. Liem, MD1, Cynthia Rigsby, MD2*, Richard J. Labotka, MD3, Andrew DeFreitas4* and Alexis A. Thompson, MD, MPH5

1Hematology, Oncology & Stem Cell Transplant, Children's Memorial Hospital, Chicago, IL
2Medical Imaging, Children's Memorial Hospital, Chicago, IL
3Pediatric Hematology and Oncology, University of Illinois at Chicago, Chicago, IL
4Cardiology, Children's Memorial Hospital, Chicago, IL
5Hematology-Oncology, Children's Memorial Hospital, Chicago, IL

T2* MRI Provides No Evidence for Myocardial and Pancreatic Iron Overload in Multitransfused Patients with Sickle/β-Thalassemia

Hussam Ghoti1*, Orly Goitein2*, Elie Konen2*, Ariel Koren, MD3*, Carina Levin3*, Alan Berebi4*, Pinhas Stark, MD5 and Eliezer Rachmilewitz, MD1

1Hematology, Edith Wolfson Medical Center, Holon, Israel
2Cardiovascular imaging diagnostic radiology, chaim Sheba medical center, Tel-Hashomer, Tel-Aviv, Israel
3Pediatric Hematology Unit, Ha'Emek Medical Center, Afula, Israel
4Hematology, Kaplan Medical Center, Rehovot, Israel
5Comprehensive Center of Thalassemia & Hemoglobinopathies, Institute of Hematology, Petah Tikva, Israel

Oxygen Desaturation at Rest and after Exercise in Pediatric Sickle Cell Disease Patients: Correlations with Hemolysis and Elevated Tricuspid Regurgitant Jet Velocity

Andrew D. Campbell, MD1, Caterina Minniti, MD2*, Sohail R Rana, MD3*, Onyinye C. Onyekwere, MD, MS4, Mehdi Nouraie, MD, PhD5*, Manuel Arteta, MD6*, Craig Sable, MD7*, Gregory Ensing, MD8*, Niti Dham, MD7*, Deepika S. Darbari9*, Lori Luchtman-Jones, MD10, Gregory J. Kato, MD11, Mark Gladwin, MD2, Oswaldo Castro, MD4* and Victor R. Gordeuk, MD4

1Pediatric Hematology/Oncology, Univ. of Michigan Medical Center, Ann Arbor, MI
2Vascular Medicine Branch, NHLBI, Bethesda, MD
3Department of Pediatrics and Child Health, Howard University Hospital, Washington, DC
4Center for Sickle Cell Disease, Howard University Hospital, Washington, DC
5Center for Sickle cell Disease, Howard University Hospital, Washington, DC
6Pediatric Pulmonary, Univ. of Michigan Medical Center, Ann Arbor, MI
7Cardiology, Children's National Medical Center, Washington, DC
8Pediatric Cardiology, Univ. of Michigan Medical Center, Ann Arbor, MI
9Pediatric Hematology/Oncology, Johns Hopkins University School of Medicine, Baltimore, MD
10Hematology, Children's National Medical Center, Washington, DC
11Pulmonary and Vascular Medicine Branch, NHLBI, Bethesda, MD

Daytime Steady-State Hemoglobin Saturation Is a Determinant of Cerebral Artery Blood Flow Velocity in Children with Sickle Cell Anemia

Jennifer Variste, BS1*, Michael M. Dowling, MD, PhD2* and Charles T. Quinn, MD, MS1

1Pediatrics, U.T. Southwestern Med. Ctr., Dallas, TX
2Pediatric Neurology, U.T. Southwestern Med. Ctr., Dallas, TX

Improved Survival of Children and Adolescents with Sickle Cell Disease

Charles T. Quinn, MD, MS1, Kimberly Thomas, BS2*, Zora R. Rogers, MD1 and George R. Buchanan, MD1

1Pediatrics, U.T. Southwestern Medical Center, Dallas, TX
2Pediatric Sickle Cell Program, Children's Medical Center Dallas, Dallas, TX

Mortality in Sickle Cell Patient Transitioning from Pediatric to Adult Program: 10 Years Grady Comprehensive Sickle Cell Center Experience

Simbo O Aduloju, MD1*, Sheila Palmer, PAC2* and James R. Eckman, MD3

1Hematology & Oncology, Emory University School of Medicine, Atlanta, GA
2Sickle Cell, Grady Health System, Atlanta, GA
3Hematology&Oncology, Emory University, Atlanta, GA

Hydroxyurea Treatment of Children with Sickle Cell Disease Inhibits RBC Membrane Degradation by Secretory Phospholipase a2

James B Ball, MD1, Samina Y Khan, BS1*, Nathan JD McLaughlin, BS1*, Rachelle Nuss2, Laura Cole, RN2* and Christopher C. Silliman, MD, PhD3

1Research, Bonfils Blood Center, Denver, CO
2The Children's Hospital, Aurora, CO
3Bonfils Blood Center, Denver, CO

Multi-Modal Intervention for Inpatient Management of Sickle Cell Pain Significantly decreases the rate of Acute Chest SyndromeClinically Relevant Abstract

Megan Reagan1*, Michael R. DeBaun, MD, MPH2 and Melissa Frei-Jones, MD, MSCI1*

1Pediatrics, Washington University School of Medicine, St. Louis, MO
2Pediatrics and Genetics, Washington Univ., Saint Louis, MO

Recruitment of Infants with Sickle Cell Anemia to a Phase III Trial:Data from the BABY HUG Study

Lynn W Wynn, MSN, CPNP1*, Lane Faughnan, RN, BSN, CCRP2*, Daner Li, MS3*, Winfred Wang, MD4, Brenda Martin, MSN, CPNP5*, Tracy Kelly, MSN, CPNP6*, Caroline Reed, MSN, FNP-C7*, Phillip Seaman, PA-C8*, Joan Marasciulo, RN9*, Elizabeth Rackoff, RN, BSN10*, Scott T. Miller, MD11, Tally Hustace, ARNP12*, Glenda Thomas, RN13*, Jennifer Marshall, RN, ADN14*, Jennifer McDuffie, MSN, CRNP15*, MaryLou MacDermott, CRNP16*, Ellen Debenham, RN, CCRC17*, Mary Murphy, MSN, CNP18*, Renee C. Rees, PhD19* and for The BABY HUG Investigators20*

1Hematology, St. Jude Children's Research Hospital, Memphis, TN
2St. Jude Children's Research Hospital, TN
3Clinical Trials & Survey Corp., MD
4St. Jude Children's Research Hospital, Memphis, TN
5Children's National Medical Center, DC
6Duke University Medical Center, NC
7Howard University, DC
8Johns Hopkins University School of Medicine, MD
9Sinai Hospital of Baltimore, Baltimore, MD
10Medical University of South Carolina, SC
11SUNY - Brooklyn, NY
12University of Miami School of Medicine, Miami, FL
13University of Mississippi Medical Center, MS
14Children's Medical Center of Dallas/UTSW, TX
15University of Alabama at Birmingham, AL
16Drexel University, PA
17Children's Healthcare of Atlanta, Atlanta, GA
18Wayne State University, MI
19Clinical Trials & Surveys, Corp., Baltimore, MD
20Clinical Trials & Survey Corp., Baltimore, MD

Safety and Efficacy of High Dose Intravenous Desferoxamine for Reduction of Iron Overload Due to Chronic Transfusion in Sickle Cell PatientsClinically Relevant Abstract

Ram Kalpatthi, MD1, Brittany Peters1*, David Holloman2*, Elizabeth Rackoffe1*, Deborah Disco1*, Sherron Jackson1* and Miguel Abboud, MD3*

1Pediatric Hematology Oncology, Medical University of South Carolina, Charleston, SC
2Pathology and Laboratory Medicine, Medical University of South Carolina, Charleston, SC
3Children's Cancer Center of Lebanon, Beirut, Lebanon

Circulating Microparticles, Plasma Protein C and Free Protein S Levels in Children with Sickle Cell Anemia

Andrea Piccin, MD1*, Elva Eakins, B.Sc, M.Sc2*, Ciaran V Murphy, B.A., Mod2*, William G Murphy, MD2*, Corrina McMahon, MD1 and Owen Smith, MD1*

1Our Lady's Children's Hospital, Dublin 12, Ireland
2Product Development, Irish Blood Transfusion Service, Dublin 8, Ireland

Dominant Role for SDF-1 in the Vasculo-Angiogenesis Phenotype in Children with Sickle Cell Disease

Beatrice E Gee, M.D.1, Jerry M Manlove-Simmons, B.S2*, Yao Huang, M.S.1*, Nana Wilson, B.S.3*, Jonathan Stiles, Ph.D.3* and Solomon Fiifi Ofori-Acquah, PhD4

1Pediatrics, Morehouse School of Medicine, Atlanta, GA
2Cardiovascular Research Institute, Morehouse School of Medicine, Atlanta, GA
3Microbiology, Biochemistry & Immunology, Morehouse School of Medicine, Atlanta, GA
4Aflac Cancer Center/Blood Disorders Services, Emory University, Atlanta, GA

Carbon Monoxide Decreases Leukocytosis in Murine Sickle Cell Disease Models Via Decreased Granulopoiesis

Joan D Beckman, BS1*, Julie V. Vineyard, BS1*, Chunsheng Chen, PhD1*, Julia Ngyuen, BS1*, Michael O Nwaneri, M.D.1*, Paul Marker, BS1*, John D. Belcher, Ph.D.1* and Gregory M. Vercellotti, MD2

1Division of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, MN
2Medical School, University of Minnesota, Minneapolis, MN

Prevalence and Complications of Obesity in Sickle Cell Disease

Anna B Halpern, BA1*, Jennifer JG Welch, MD2, Priya Hirway, MS3* and Anjulika Chawla, MD4

1Pediatric Hematology Oncology, Alpert Medical School of Brown University, Providence, RI
2Pediatric Hematology Oncology, Hasbro Children's Hospital/Brown University, Providence, RI
3Community Health, Brown University, Providence, RI
4Hasbro Children Hospital, Providence, RI

Pulmonary Function in Children with Sickle Cell Anemia Following Treatment with HydroxyureaClinically Relevant Abstract

Elizabeth Record, MSN, DNP1*, Tamara New, MD2*, Randall Brown, MD, MPH3*, LeRoy Graham, MD3* and R. Clark Brown, MD, PhD2

1AFLAC Cancer Ctr. & Blood Disorders Svc., Children's Healthcare of Atlanta, Atlanta, GA
2AFLAC Cancer Ctr. & Blood Disorders Svc., Emory University and Children's Healthcare of Atlanta, Atlanta, GA
3Georgia Pediatric Pulmonary Associates, PC, Atlanta, GA

Transcranial Doppler (TCD) Ultrasonography in Infants with Sickle Cell Anemia:  Baseline Data from the BABY HUG Trial

Winfred Wang, MD1, Renee C Rees, PhD2*, Scott T. Miller, MD3, R. Clark Brown, MD, PhD4, James F. Casella, MD5, Rathi V. Iyer, MD6*, Ram V. Kalpathi, M.D.7*, Judy Luden8*, Zora R. Rogers, MD9, Courtney Thornberg, M.D.10*, Robert J. Adams, MD7, Steven Pavlakis, MD11* and the BABY HUG Investigators12*

1St. Jude Children's Research Hospital, Memphis, TN
2Clinical Trials & Surveys, Corp., Baltimore, MD
3SUNY - Brooklyn, Brooklyn, NY
4AFLAC Cancer Ctr. & Blood Disorders Svc., Emory University / Children's Healthcare of Atlanta, Atlanta, GA
5Pediatrics, Johns Hopkins Univ. School of Med., Baltimore, MD
6Pediatrics, University of Mississippi Medical Center, Jackson, MS
7Medical University of South Carolina, Charleston, SC
8Medical College of Georgia, Augusta, GA
9Department of Pediatrics, UT Southwestern Medical Center, Dallas, TX
10Duke University Medical Center, Durham, NC
11Maimonides Medical Center, Brooklyn, NY
12C-TASC, Baltimore, MD

Antecedent Transfusion and Primary Hemorrhagic Stroke in Adults with Sickle Cell DiseaseClinically Relevant Abstract

John J. Strouse, MD1, Joshua J. Field, MD2, Regina D. Crawford, M.D.3* and Sophie Lanzkron, MD4

1Div. of Pediatric Hematology, Johns Hopkins Univ., Baltimore, MD
2Washington University, Saint Louis, MO
3Division of Hematology, Duke University, Durham, NC
4Johns Hopkins Univ., Baltimore, MD

Elevated Circulating Stromal Derived Factor-1 Levels in Sickle Cell Disease

Precious Landburg, MD1*, Erfan Nur, MD2*, Naomi Maria1*, B. J. Biemond3, Dees P. Brandjes, MD, PhD4*, John-John Schnog, MD, PhD1 and Ashley Duits, PhD1

1Red Cross Blood Bank Foundation, Curacao, Netherlands Antilles
2Internal Medicine, Slotervaart Hospital, Amsterdam, Netherlands
3Academic Medical Center, Amsterdam, Netherlands
4Department of Internal Medicine, Slotervaart hospital, Amsterdam, Netherlands

The Mechanism of Hemolysis in Sickle Cell Anemia

Tennille Presley, PhD1*, Lauren Bain1*, Samir Ballas, MD2*, James Nichols, RN3*, Hernan Sabio, MD4, Mark Gladwin, MD3*, Gregory J. Kato, MD5 and Daniel Kim-Shapiro, PhD6

1Physics, Wake Forest University, Winston Salem, NC
2Cardeza Foundation for Hematologic Research, Thomas Jefferson University, Philadelphia, PA
3Critical Care Medicine Department, Clinical Center, National Institutes of Health, Bethesda, MD
4Pediatrics, Wake Forest Univ., Winston Salem, NC
5Pulmonary and Vascular Medicine Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD
6Olin Physical Lab., Wake Forest University, Winston Salem, NC

Hb Dothan [β25/26 (B7/B8) / (-GTG/-GLY) / Gly+Glu→Glu]; A Novel Mechanism Leading to a M-Hemoglobin

Ferdane Kutlar, MD1, Lee Hilliard, MD2, Lina Zhuang, MD3*, Niren Patel, MBBS1* and Abdullah Kutlar, MD3

1Sickle Cell Center, Medical College of Georgia, Augusta, GA
2Children's Hosp. of Alabama, The University of Alabama at Birmingham, Birmingham, AL
3Medical College of Georgia, Augusta, GA

In Vitro Exploratory Studies of Haptoglobin Polymorphisms and Their Effect on Cytokine Release from Cultured Mononuclear Cells in Sickle Cell Disease

Komal Bora1*, Kavita Natarajan, MBBS1, Ferdane Kutlar, MD2, Hanfang Zhang, MD, PhD2*, Hongyan Xu, PhD2*, Betsy Clair2*, Kathleen M McKie, MD2* and Abdullah Kutlar, MD1

1Medical College of Georgia, Augusta, GA
2Sickle Cell Center, Medical College of Georgia, Augusta, GA

Genomic Approaches to Identifying Risk for Pulmonary Artery Hypertension among Individuals with Sickle Cell Disease

Damian Silbermins, MD1, Laura M. De Castro, MD2, Jude C Jonassaint, RN2*, Shiaowen David Hsu, MD, PhD3*, Marilyn J. Telen, MD3 and Jen-Tsan Chi, MD, PhD4*

1Medicine, Duke University, Durham, NC
2Comprehensive Sickle Cell Center, Clin. Director Duke Adult, Durham, NC
3Medicine, Duke University Medical Center, Durham, NC
4Duke Institute for Genome Science and Policy, Duke University, Durham, NC

Pulmonary Hypertension Is Not Associated with An Increased Risk of Death in Children with Sickle-Cell Disease Followed for a Mean of 3 Years

Margaret T. Lee, MD, Tania Small, MD*, Muhammad Amar Khan, MD*, Erika Berman Rosenzweig, MD*, Robyn J. Barst, MD* and Gary M. Brittenham, MD

Columbia University, New York, NY

Phosphodiesterase-4 Inhibition Reduces Ischemic/Reperfusion Liver Injury in a Mouse Model for Sickle Cell Disease

Alida Filippini1*, Giorgio Malpeli2*, Anne Janin3*, Orah S Platt4*, Christhope Leboeuf5*, Aldo Scarpa2*, Yves Beuzard6* and Lucia De Franceschi, MD1

1Clinical and Experimental Med., Policlinico GB Rossi, Univ. of Verona, Verona, Italy
2Pathology, University of VErona, Verona, Italy
3Université Paris Diderot-Paris 7/Inserm U728, AP HP Hôpital Saint Louis, Paris, France
4Lab of Medicine, Children's Hospital, Boston, MA
5Inserm 02 20, Laboratorie de Pathologie, Hopital S Louis, Paris, France
6Lab of Hematopoietic Gene Therapy, Hopital S Louis, Paris, France

Prolonged Administration of Hydroxyurea Reduces Morbidity and Mortality in Adult Patients with Sickle-Cell Syndromes: Long-Term Experience of a Single CenterClinically Relevant Abstract

Ersi Voskaridou1*, Antonios Bilalis1*, Dimitrios Christoulas2*, Konstantinos Varvagiannis1*, Kleio Sinopoulou1*, Eleni Plata1*, Panagiotis Tsaftaridis1*, Dimitris Loukopoulos3* and Evangelos Terpos2

1Thalassemia Center, Laikon General Hospital, Athens, Greece
2Department of Hematology & Medical Research, 251 General Air Force Hospital, Athens, Greece
3Haematology Research Laboratory, Biomedical Research Foundation, Academy of Athens, Athens, Greece

Genome-Wide Association Studies Suggest Shared Polymorphisms Are Associated with Severity of Sickle Cell Anemia and Exceptional Longevity

Paola Sebastiani, PhD1*, Nadia Timofeev, MS1*, Steven H. Hartley, MS1*, Daniel Dworkis, BS2*, Lindsay Farrer, PhD3*, Clinton T. Baldwin, PhD4*, Thomas T. Perls, MD3* and Martin H. Steinberg, MD5

1Biostatistics, Boston University School of Public Health, Boston, MA
2Boston University School of Medicine, Boston, MA
3Medicine, Boston University School of Medicine, Boston, MA
4Center for Human Genetics, Boston, MA
5Department of Medicine/Division of Hematology and Oncology, Boston University School of Medicine, Boston, MA

Placenta Growth Factor Induces 5-Lipoxygenase-Activating Protein Via Hypoxia-Inducible Factor-1α and Contributes to Increased Leukotrienes in Sickle Cell Disease

Vijay K Kalra, PhD1*, Nitin Patel, PhD1*, Caryn Gonsalves, MS1*, Minyang Yang, PhD2* and Punam Malik2

1Biochemistry and Molecular Biology, USC Keck School of Medicine, Los Angeles, CA
2Div. of Experimental Hematology and Cancer Biology, Dept of Pediatrics, Cincinnati Childrens Hospital Medical Center, Cincinnati, OH

*signifies non-member of ASH